These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35976670)

  • 1. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
    Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
    Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Yu MW; Lin CL; Liu CJ; Wu WJ; Hu JT; Huang YW
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
    Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
    Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
    JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.
    Liu L; Xie S; Teng YX; Deng ZJ; Chen K; Liu HT; Huo RR; Liang XM; Guo PP; Yang DL; Ma L; Xiang BD; Li LQ; Zhong JH
    Front Oncol; 2021; 11():783339. PubMed ID: 35127490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
    Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
    Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
    Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
    Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
    Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
    BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.
    Wang QX; Xue J; Shi MJ; Xie YB; Xiao HM; Li S; Lin M; Chi XL
    Diabetes Metab Syndr Obes; 2022; 15():2311-2322. PubMed ID: 35942038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
    Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
    Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
    Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
    Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
    World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
    Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
    Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.